Combination/sequential therapy in osteoporosis
Tóm tắt
Combination therapy includes the concomitant or sequential use of compounds sharing the same mode of action (eg, two or more inhibitors of bone resorption) or with distinct pathways of activity (eg, an inhibitor of resorption plus an anabolic agent). Combination use of antiresorptive agents may generate concerns, because of the risk of inducing oversuppression of bone turnover. However, if low doses of estrogen, used for the management of climacteric symptoms, are insufficient to normalize bone turnover, the addition of a bisphosphonate to hormone therapy may prove to be useful to achieve this objective. Patients pretreated with inhibitors of resorption, who have not achieved a full therapeutic response, are good candidates for treatment with anabolic agents. The increase in bone turnover that comes after the introduction of parathyroid hormone (PTH) in patients treated with an antiresorptive agent is similar to that observed in treatment-naíve patients and the pattern of bone mineral density (BMD) increase is also identical, with the exception of a 6 month delay in the spine and hip BMD changes observed in prior alendronate-treated subjects. Current data discourage the concomitant use of alendronate and PTH since the bisphosphonate appears to blunt (in men and women) the anabolic action of PTH. Whether this applies to other bisphosphonates or inhibitors of resorption, remains unknown. The use of an inhibitor of bone resorption after completion of PTH treatment seems an appropriate way to maintain the skeletal benefits gained during therapy. Long-term clinical studies, using fractures as an endpoint should be initiated to better understand the clinical and pharmaco-economic interest of combination therapies in the management of osteoporosis.
Tài liệu tham khảo
Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018–2026.
Lufkin EG, Wahner HW, O’Fallon WM, et al.: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1–9.
Chesnut C III, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000, 109:267–276.
Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999, 282:637–645.
Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535–1541.
Meunier PJ, Sebert JL, Reginster J-Y, et al.: Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVO Study Group. Osteoporos Int 1998, 8:4–12.
Reginster JY, Meurmans L, Zegels B, et al.: The effect of sodium monofluorophosphatase plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998, 129:1–8.
Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441. The first methodologically sound study unequivocally demonstrating the antifracture efficacy of an anabolic agent in the management of osteoporosis.
Rubin MR, Cosman F, Lindsay R, Bilezikian JP: The anabolic effects of parathyroid hormone. Osteoporos Int 2002, 13:267–277.
Meunier PJ, Roux C, Seeman E, et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459–468. The demonstration that a compound able to concomitantly reduce bone resorption and stimulate bone formation is able to reduce vertebral fracture rates in postmenopausal osteoporosis.
Reginster J-Y, Minne HW, Sorensen OH, et al.: Randomized trial of the effect of risedronate on vertebral fractures in momen with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83–91.
Riis BJ, Ise J, Von Stein T, et al.: Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001, 16:1871–1878.
Storm T, Thamsborg G, Steiniche T, et al.: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990, 322:1265–1271.
Bone HG, Adami S, Rizzoli R, et al.: Weekly administration of alendronate: rationale and plan for clinical assessement. Clin Ther 2000, 22:1–14.
Adami S, Felsenberg D, Christiansen C, et al.: Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004, 34:881–889.
Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653–661.
Boonen S, Rizzoli R, Meunier PJ, et al.: The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004, 15:511–519.
Mashiba T, Hirano T, Turner CH, et al.: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613–620.
Wimalawansa SJ: Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents. J Clin Densitom 2000, 3:187–201.
Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333.
Lindsay R, Cosman F, Lobo RA, et al.: Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999, 84:3076–3081.
Greenspan SL, Resnick NM, Parker RA: Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. A randomized controlled trial. JAMA 2003, 289:2525–2532.
Greenspan SL, Emkey RD, Bone HG III, et al.: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 137:875–883.
Bone HG, Greenspan SL, McKeever C, et al.: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000, 85:720–726.
Davas I, Altintas A, Yoldemir T, et al.: Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. Menopause 2003, 80:536–540.
Tiras MB, Noyan V, Yildirim M, Daya D: Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 2000, 15:2087–2092.
Palomba S, Orio F, Colao A, et al.: Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:1502–1508.
Wimalawansa SJ: Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995, 99:36–42.
Wimalawansa SJ: A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998, 104:219–226.
Harris ST, Eriksen EF, Davidson M, et al.: Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001, 86:1890–1897.
Wimalawansa SJ, Stevenson JC, Banks LM, et al.: Prevention of postmenopausal bone loss with small doses of calcitonin and percutaneous oestrogen. In Recent Research on Gynecological Endocrinology. Edited by Genazzani AR, Petraglia F, Volpe A, Facchinetti F. London: Parthenon Publishers; 1998:239–244.
Meschia M, Brincat M, Barbacini P, et al.: A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993, 53:17–20.
de Aloysio D, Gambacciani M, Altieri P, et al.: Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol Endocrinol 1997, 11:289–293.
Johnell O, Scheele WH, Lu Y, et al.: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:985–992.
Frost HM: Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orthop 1979, 143:227–244.
Lindsay R, Nieves J, Formica C, et al.: Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550–555.
Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925–931.
Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998, 102:1627–1633. An interesting study performed in patients with corticosteroidinduced osteoporosis showing that PTH treatment may be initiated in patients receiving chronic HT.
Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944–951.
Ettinger B, San Martin J, Crans G, Pavo I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745–750. The demonstration that PTH treatment may be initiated in patients previously treated with raloxifene or alendronate.
Hesch R-D, Busch U, Prokop M, et al.: Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989, 44:176–180.
Hodsman AB, Fraher LJ, Watson PH, et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997, 82:620–628.
Reeve J, Bradbeer JN, Arlot M, et al.: hPTh 1–34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1991, 1:162–170.
Bradbeer JN, Arlot ME, Meunier PJ, Reeve J: Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol 1992, 37:282–289.
Mosekilde L, Danielson CC, Gasser J: The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone (1-38), and combination therapy, assess in aged ovariectomized rats. Endocrinology 1994, 134:2126–2134.
Li M, Mosekilde L, Sogaard CH, et al.: Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 1995, 16:629–635.
Hock JM, Hummert JR, Boyce R, et al.: Resorption is not essential for the stimulation of bone growth by hPTH(1-34) in rats in vivo. J Bone Miner Res 1989, 4:449–458.
Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ: PTH has more pronounced effect on vertebral bone mass and biochemical competence than antiresorptive agents (estrogen and bisphosphonate) assessed in sexually mature, ovariectomized rats. Bone 1994, 15:401–408.
Delmas PD, Vergnaud P, Arlot ME, et al.: The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption in inhibited by the bisphosphonate tiludronate. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system? Bone 1995, 16:603–610.
Mosekilde L, Thomsen JS, Kneissel M, Gasser JA: Alendronate blunts the anabolic effect of a PTH analog, SDZ PTS 893, when administered sequentially. J Bone Miner Res 1997, 12:S343.
Cosman F, Nieves J, Woelfert L, et al.: Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998, 13:1051–1055.
Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207–1215. This study reports the absence of synergistic effect of alendronate and PTH and concludes that this association should not be recommended in the management of osteoporosis.
Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216–1226.
Khosla S: Parathyroid hormone plus alendronate - A combination that does not add up. N Engl J Med 2003, 349:1277–1279.
Morabito N, Gaudio A, Lasco A, et al.: Three-year effectiveness of intravenous pamidronate versus pamidronate plus slowrelease sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 2003, 14:500–506.
Alexandersen P, Riis BJ, Christiansen C: Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab 1999, 84:3013–3020.
Gutteridge DH, Stewart GO, Prince RL, et al.: A randomized trial of sodium fluoride (60 mg) + estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 2002, 13:158–170.
Reginster J-Y, Agnusdei D, Gennari C, Kicovic PM: Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Gynecol Endocrinol 1999, 13:361–368.
Reginster J-Y, Felsenberg D, Pavo I, et al.: Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 2003, 14:741–749.
Erdtsieck RJ, Pols HAP, Valk NK, et al.: Treatment of postmenopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Clin Endocrinol 1995, 43:557–565.
Holloway L, Kohlmeier L, Kent K, Marcus R: Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 1997, 82:1111–1117.
Murphy MG, Weiss S, McClung M, et al.: Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001, 86:1116–1125.
Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Met 2000, 85:2129–2134.
Rhee Y, Won Y-Y, Baek M-H, Lim S-K: Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats. J Bone Miner Res 2004, 19:931–937.
Maalouf N, Wehbe J, Nehme A, et al.: Osteoporosis: combination therapy for better or worse. J Musculo Neuron Interact 2003, 3:141–147.